๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ
13.4K subscribers
1.33K photos
11 videos
555 files
687 links
ุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู…

ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ

ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ:
ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ
ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ
ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ
ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„
ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ
ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ

ู„ู„ุชูˆุงุตู„:
Insta: hussian_8x

@AronX2bot
Download Telegram
Applied Therapeutic ฤฑฤฑ
โ—โ—‹โ—‹โ—โ—‹โ—‹โ—โ—‹โ—‹โ—
ุจุงู„ุงุนุชู…ุงุฏ ุนู„ู‰ ุงู„ู…ู†ู‡ุฌ ุงู„ู…ูˆุญุฏ ูขู ูขูฆ

1. Adrenal Gland Disorders
โ—PDF โ—Explain

2. Thyroid Gland Disorders
โ—PDF โ—Explain

3. Alzheimer Disease
โ—PDF โ—Explain

4. Anxiety Disorders
โ—PDF โ—Explain

5. Depressive Disorders
โ—PDF โ—Explain

6. Schizophrenia
โ—PDF โ—Explain

7. Insomnia
โ—PDF โ—Explain

8. Contraception
โ—PDF โ—Explain

9. Hormone Replacement Therapy
โ—PDF โ—Explain

10. Menstruation Related Disorders
โ—PDF โ—Explain

11. Cancer Chemotherapy & Treatment
โ—PDF โ—Explain

12. Leukemias
โ—PDF โ—Explain

13. Lymphomas
โ—PDF โ—Explain

14. Breast Cancer
โ—PDF โ—Explain

15. Prostate Cancer
โ—PDF โ—Explain

16. Adverse Effects Of Chemotherapy
โ—PDF โ—Explain

All Lectures

๐“„ผ๐“„น๐“„ผ๐“„น๐“„ผ๐“„น๐“„ผ๐“„น๐“„ผ๐“„น๐“„ผ๐“„น๐“„ผ๐“„น๐“„ผ๐“„น๐“„ผ๐“„น๐“„ผ๐“„น๐“„ผ๐“„น๐“„ผ๐“„น๐“„ผ๐“„น๐“„ผ๐“„น๐“„ผ๐“„น๐“„ผ๐“„น๐“„ผ
ุญู„ูˆู„ ุงุณุฆู„ุฉ ุงู„ุนู„ุงุฌูŠุงุช ู„ู„ุฏูˆุฑ ุงู„ุงูˆู„ 2026

#ุดุฎุงุจูŠุท

Notes:
#adrenal_disorders
#thyroid_disorders
#alzheimer
#MDD
#anxiety
#schizophrenia
#insomnia
#contraception
#HRT
#MRD
#Leukemia
#Lymphoma
#Breast_Cancer
#Prostate_Cancer
#ad_effect_CT

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ
โค141๐Ÿ™5๐Ÿ’”4๐Ÿ’ฏ2๐Ÿ˜ญ2
A 66 years old woman is suffering from low mineral bone density and strong family history of breast cancer.

What would be the best protective agent? #Breast_Cancer
Anonymous Quiz
34%
a- Tamoxifen
50%
b- Raloxifene
8%
c-Exemestane
6%
d- Cyclophosphamide
2%
e- None of them
โค5
โค7๐Ÿ‘1
๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ
#Breast_Cancer
Drug used to prevent Breast cancer.

Which drug increased incidence of endometrial cancer

a- Exemestane
b- anastrozole
c- tamoxifen
d- raloxifene
e- Letrozole

ูˆุฒุงุฑูŠ ุฏูˆุฑ ุงูˆู„ 2024

ุงู„ุญู„ ู…ู† ุงู„ุตูˆุฑุฉ ๐Ÿซ†

#Breast_Cancer
โค8๐Ÿ’Š1
Which genetic mutations significantly incrcase the lifetime risk of breast cancer?

a- BRCA1 and BRCA2
b- TPS3 and EGFR
c- KRAS and NRAS
d- ATM and CHEK2
e- BRCA3 and PALB2

ุฏูˆุฑ ุงูˆู„ 2024
ุทุจุนุง ู‡ุงูŠ ุงู„ุงุณุฆู„ุฉ ุชุฎุต ุงูˆู„ ู…ุญุงุถุฑุฉ ู†ุฒู„ุชู‡ุง ุงู„ูƒู…

ุงู„ู…ุญุงุถุฑุฉ ุงู„ุฌุงูŠุฉ ุนู„ุงุฌุงุช ุงู„ breast cancer

ุณุคุงู„ ุณู‡ู„ ูˆุญุชู‰ ู…ุชู†ุณูˆู† Breast Cancer ู‡ูˆ BR CA

#Breast_Cancer
โค7
๐Ÿ™2โค1
An intramuscular agent, is approved for second line therapy of postmenopausal patients with hormone receptor-positive breast cancer either alone or in combination with targeted therapy?

A) Tamoxifen
B) Raloxifene
C) Toremifene
D) pertuzumab
E) Fulvestrant

ุจู…ุญุงุถุฑุฉ ุงู„ breast cancer ูู‚ุท ุฏูˆุงุก ูˆุงุญุฏ ู…ุฐูƒูˆุฑ ุงู†ู‡ ู†ู†ุทูŠู‡ im ูŠุนู†ูŠ ุจุฏูˆู† ู…ุง ุชูƒู…ู„ ุงู„ุณุคุงู„ ุชุฎุชุงุฑ ูˆุงู†ุช ู…ุบู…ุถ
ูˆูƒู„ุงู… ุงู„ุณุคุงู„ ู†ุตุง ู…ู† ุงู„ู…ู„ุฒู…ุฉ ู…ุงูƒูˆ ู…ุนู„ูˆู…ุฉ ู…ู…ูŠุฒุฉ ู…ุฌุฑุฏ ู…ุนู„ูˆู…ุฉ ุฏุฑุฎูŠุฉ

ูˆุฒุงุฑูŠ 25 ุฏูˆุฑ 1

#Breast_Cancer
โค5๐Ÿ’ฏ1
ุทู„ุงุจ

ู‡ูˆ ุงุฐุง Hormone receptor Positive ุงูƒูŠุฏ ู†ุณุชุฎุฏู… endocrine therapy ู ุดู†ูˆ ู‡ุงู„ุชู†ุงู‚ุถ ุจู‡ุงูŠ ุงู„ุตูˆุฑุฉ

ู‡ู†ุง ุงูƒูˆ ุฎุทุฃ ุจุงู„ู…ู†ู‡ุฌ ุงู„ู…ูˆุญุฏ ูˆุฑุฌุนุช ุชุฃูƒุฏุช ู…ู† ุงู„ู…ุตุฏุฑ ูƒุงุชุจ negative ูˆู‡ุฐุง ุงู„ุตุญ

ููŠ ุญุงู„ุฉ
Hormone receptor Negative
ู‡ู†ุง ู…ุง ู†ู†ุทูŠ endocrine therapy ูˆู†ุจุฏูŠ ุจุงู„ุนู„ุงุฌ ุงู„ูƒูŠู…ูŠุงูˆูŠ


ูŠุนู†ูŠ ู…ุฎุชุตุฑ ุงู„ุนุจุงุฑุฉ ุจุดูƒู„ ูƒุงู…ู„

ููŠ ุญุงู„ุฉ Hormone receptorโ€“negative tumors (ER-/PR-)
ู‡ุฐูˆู„ ุงู„ู…ุฑุถู‰ ู…ุง ูŠุณุชููŠุฏูˆู† ู…ู† ุงู„ุนู„ุงุฌ ุงู„ู‡ุฑู…ูˆู†ูŠ ุฃุตู„ุงู‹ุŒ
ู„ุฐู„ูƒ ุงู„ุนู„ุงุฌ ุงู„ูƒูŠู…ูŠุงุฆูŠ ูŠูƒูˆู† ุฎูŠุงุฑ ุฃุณุงุณูŠ ู…ู† ุงู„ุจุฏุงูŠุฉ



ุจุญุงู„ุฉ Triple Negative Breast Cancer
ูŠุนู†ูŠ: -ER- , PR- ,HER2

ู…ุงูƒูˆ ูˆู„ุง ู‡ุฏู ู…ูˆุฌูˆุฏ ู„ุง ุฌูŠู†ูŠ ูˆู„ุง ู‡ุฑู…ูˆู†ูŠ
ุŒ ู„ุฐู„ูƒ ุงู„ุนู„ุงุฌ ุงู„ุฑุฆูŠุณูŠ ูŠูƒูˆู† ุงู„ูƒูŠู…ูŠุงูˆูŠ



ุงู…ุง ุจุงู„ุงุฎูŠุฑ ู‡ู†ุง ุฑูƒุฒูˆุง
ุงุฐุง ุงู„ุญุงู„ุฉ Hormone receptorโ€“positive tumors
ู‡ู†ุง ู†ุจุฏูŠ ุจู€ ุงู„ุนู„ุงุฌ ุงู„ู‡ุฑู…ูˆู†ูŠ ยฑ ุนู„ุงุฌ ู…ูˆุฌู‡ ุŒ ู„ูƒู†

ู†ู„ุฌุฃ ู„ู„ูƒูŠู…ูŠุงูˆูŠ ุฅุฐุง ูุดู„ ุงู„ุนู„ุงุฌ ุงู„ู‡ุฑู…ูˆู†ูŠ


ุตูุญุฉ ูกูข ุจุงู„ู…ู„ุฒู…ุฉ
ูˆุตูุญุฉ ูฆ ุจู…ู„ุฒู…ุฉ ุงู„ูˆุฒุงุฑุฉ

#Breast_Cancer

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ
โค9
Prevention of Breast Cancer

In higher risk patients:
Mastectomy, oophorectomy, pharmacological Therapy

Pharmacological Therapy: SERM, AI

โญ• SERM: Tamoxifein, Raloxifene for 5 years



ุงู„ุชุงู…ูˆูƒุณููŠู† ูŠุณุจุจ ุฒูŠุงุฏุฉ ููŠ ุฎุทุฑ ุญุตูˆู„ ุงู„ endometrial cancer

ูˆุงุซู†ูŠู†ู‡ู… ู…ู…ูƒู† ูŠุณุจุจูˆู† thromboembolic events


โญ• Aromatase inhibitors: Exemestane, Anastrozole



๐Ÿซ† Postmenopausal women with high risk of contralateral primary breast cancer โž” Aromatase inhibitors AI

ุงู„ guidelines ุชูˆุตูŠ ุจุงุณุชุฎุฏุงู… ุงู„ู€ serm+AI ู„ู…ู†ุน ุงู„ breast cancer ููŠ ุงู„ postmenopausal women ุจุณ ู…ู†ูˆ ู…ู† ุงู„ sermุŸ
Raloxifene


๐Ÿซ† Premenoposal women with high risk of breast cancer โž” Tamoxifein

#Breast_Cancer
โค15๐Ÿ™2๐Ÿ‘1
Treatment of Breast Cancer stage I-III

Surgery(Mastectomy, BCT)
alone can cure:
Most pt with in situ cancer
70-80% pt with stage ฤฑ
Half of pt (50%) with Stage ฤฑฤฑ


ุจุนุฏ ุงู„ุนู…ู„ูŠุฉ ู…ู…ูƒู† ู†ุณุชุฎุฏู… Radiation ู„ู„ู‚ุถุงุก ุนู„ู‰ ุจู‚ุงูŠุง ุงู„ูƒุงู†ุณุฑ


Systemic therapy: Chemotherapy, Endocrine therapy, Targeted therapy

or combination of these agents(in higher risk pt and specific prognostic factors)




โญ• Chemotherapy

Goal: cure

๐Ÿซ† Indications:

Adjuvant therapy โž” after surgery


Neoadjuvant therapy โž” before surgery in stage ฤฑฤฑฤฑ (locally advanced BC)

ุญุชู‰ ู†ู‚ู„ู„ ุญุฌู… ุงู„ูˆุฑู… ูˆู†ุณู‡ู„ ุงุฌุฑุงุก ุงู„ุนู…ู„ูŠุฉ ุงู„ุฌุฑุงุญูŠุฉ ู…ู…ูƒู† ุงู†ุทูŠ chemotherapy ู„ูˆุญุฏู‡ ุงูˆ ู…ุน
targeted(biologic) therapy, and may be endocrine therapy

Chemotherapy: doxorubicin, epirubicin, cyclophosphamide, methotrexate, fluorouracil, carboplatin, paclitaxel and docetaxel

๐Ÿซ† As adjuvant: alone or combination of chemotherapy(more effective)


๐ŸซŸ Anthracycline (doxorubicin or epirubicin) and Taxane (paclitaxel or docetaxel) โž” adjuvant treatment of breast cancer
ูŠุนุชุจุฑ ุงู„ู€
cornerstones of chemotherapy

ู†ู†ุทูŠู‡ุง ุจุนุฏ ุงู„ุนู…ู„ูŠุฉ ุงู„ุฌุฑุงุญูŠุฉ ู„ู…ุฏุฉ 12 ุงุณุจูˆุน




โญ• Biologic (targeted) Therapy

๐Ÿซ† Trastuzumab โž” mAB against HER2 receptor

ุงู†ุทูŠ ููŠ ุญุงู„ุงุช ุงู„ู€ breast cancer ุงู„ูŠ ุนุฏู‡ู… over expression HER2

ุจ combination ู…ุน Adjuvant Chemotherapy ุงูˆ ู…ุง ุจุนุฏ ุงู„ adjuvant chemotherapy

ุจุณ ู†ู†ุชุจู‡ ุงู†ู‡ ู…ู…ูƒู† ูŠุฒูŠุฏ ุฎุทุฑ ุงู„ cardiac toxicity ุงุฐุง ุงู†ุทูŠุชู‡ ู…ุน ู†ุธุงู… ุนู„ุงุฌูŠ ูŠุญุชูˆูŠ anthracycline


๐Ÿซ† Neratinib โž” TKI of EGFR, HER2, and HER4

ุงู†ุทูŠู‡ ู…ุน Adjuvant therapy ู„ูƒู† ุจุนุฏ ุงูƒู…ุงู„ ุงู„ Trastuzumab


๐Ÿซ† Ado-trastuzumab emtansine (TDM1) โž”

ู†ู†ุทูŠู‡ ู„ู„ู…ุฑุฃุฉ ุงู„ูŠ ู…ุงุฎุฐู‡ neoadjuvant ู‚ุจู„ ุงู„ุนู…ู„ูŠุฉ ุงู„ุฌุฑุงุญูŠุฉ ูˆุจุนุฏ ุงู„ุนู…ู„ูŠุฉ ุจู‚ุช ุจู‚ุงูŠุง ู…ู† ู‡ุฐุง ุงู„ูƒุงู†ุณุฑ ู†ู†ุทูŠู‡ ฺฉ adjuvant therapy




โญ• Endocrine therapy

ู†ุนุชู…ุฏ ุนู„ู‰ menopause state ููŠ ุงุฎุชูŠุงุฑ ุงู„ุนู„ุงุฌ

๐ŸซŸ Tamoxifen โž” premenoposal women
ู†ู†ุทูŠู‡ ุจุนุฏ ุงูƒู…ุงู„ ุงู„ู€ chemotherapy ู„ู…ุฏุฉ 5 ุงู„ู‰ 10 ุณู†ูˆุงุช


๐ŸซŸ Combination of LHRH (goserelin, triptorelin, and Leuprolide) + AI โž” recommended in premenoposal women

ู‡ุฐุง ุงู„ู…ูุถู„
ู„ุงู† ู‡ูˆุงูŠ ุจูŠู‡ ู…ุดุงูƒู„ ุงู„ Tamoxifen

ู„ูƒู†ุŒ ุงุฐุง ุงู„ู…ุฑุฃุฉ ู…ุนุฏู„ุงุช ุงู„ุงู†ุชูƒุงุณุฉ ุนุฏู‡ุง ู‚ู„ูŠู„ุฉ ุงูˆ ู…ุง ุชุชุญู…ู„ ุงู„ุงุซุงุฑ ุงู„ุฌุงู†ุจูŠุฉ ู„ู‡ุฐุง ุงู„ combination ู ู†ุณุชุฎุฏู… Tamoxifen

๐ŸซŸ AI (anastrozole, letrozole and exemestane) โž” Postmenopoasal women



#Breast_Cancer
โค10
Treatment of Metastatic Breast Cancer (MBC) stage IV


ุจุฏุงูŠุฉ ุงุฐุง ุงู„ูƒุงู†ุณุฑ ู…ู†ุชุดุฑ ูˆูˆุงุตู„ ู„ู„ bone ู…ู‡ู… ุฌุฏุง ุงู†ู‡ ู†ู†ุทูŠ
Modifying agent (Pamidronate, Zoledronic acid, or Denosumab)
ุญุชู‰ ู†ู‚ู„ู„ ู…ู† ุงู„ูƒุณูˆุฑ ูˆุขู„ุงู… ุงู„ุนุธุงู… ุงูˆ ุงู„ุนู…ูˆุฏ ุงู„ูู‚ุฑูŠ ูˆู‡ุงูŠ ุงู„ุญุจุดูƒู„ุงุช


โญ• Biologic Therapy

๐Ÿซ† CDK inhibitor
Abemaciclib, Palbociclib, and ribociclib โž” inhibit CDK 4, CDK6, Approved for MBC


๐Ÿซ† mTOR inhibitor
Everolimus
ูŠูˆู‚ู ุชู‚ุฏู… ุงู„ูƒุงู†ุณุฑ ุงุฐุง ุงู†ุทูŠุชู‡ ุจ combination ู…ุน ูˆุงุญุฏ ู…ู† ู‡ุฐู‡ ุงู„ุงุฏูˆูŠุฉ :
Exemestane, Fulvestrant, or Tamoxifen (mTOR + F, E, T)


๐Ÿซ† PI3k inhibitor
Apelisib โž” approved in combination with Fulvestrant

ุจุดุฑูˆุท :
๐ŸซŸ Postmenopausal women and men
๐ŸซŸ Hormone receptor positive
๐ŸซŸ HER2 negative
๐ŸซŸ PI3K mutated
๐ŸซŸ Advanced or MBC

ุงู†ุทูŠู‡ ุจุนุฏ endocrine therapy ุงุฐุง ูุดู„ ูˆุจู‚ู‰ ุงู„ู…ุฑุถ ูŠุชู‚ุฏู…

๐Ÿซ† PARP inhibitor
Olaparib, Talazoparib โž” improve progression free survival PFS in appropriate patients


๐Ÿซ† HER2 targeted agent
Trastuzumab, pertuzumab, Ado-trastuzumab emtansine, famtrastuzumab, deruxtecan, margetuximab, Lapatinib, Neratinib, and Tucatinib

๐Ÿ”ต Pertuzumab-trastuzumab and Taxane โž” first line in patients with HER2 over expression MBC
ุจุดุฑุท ุงู†ู‡ ุงู„ู…ุฑูŠุถุฉ ุณุงุจู‚ุง ู…ุง ู…ุณุชุฎุฏู…ุฉ pertuzumab ููŠ ุงู„ู…ุฑุงุญู„ ุงู„ุฃูˆู„ูŠุฉ ุณูˆุงุก adjuvant ุงูˆ neoadjuvant

๐Ÿ”ต Ado-trastuzumab emtansine โž” second line

ุงุฐุง ูุดู„ ุงู„ุฎุท ุงู„ุงูˆู„ ุงูˆ ุงู„ู…ุฑูŠุถุฉ ู…ุง ูƒุฏุฑุช ุชุชุญู…ู„ ุขุซุงุฑู‡ ุงู„ุฌุงู†ุจูŠุฉ ู†ู„ุฌุฃ ุงู„ู‰ ุงุณุชุฎุฏุงู… ู‡ุฐุง ุงู„ุนู„ุงุฌ



โญ• Endocrine Therapy

ุงุฐุง ุฌุงู†ุช ุญุงู„ุฉ MBC ู…ู† ู†ูˆุน hormone positive ู ู…ุน ุงู„ targeted therapy ู„ุงุฒู… ุงุถูŠู ุงู„ู€ endocrine therapy ูƒุฎุท ุนู„ุงุฌูŠ ุงูˆู„

ูˆู†ูุณ ุงู„ุดูŠ ุงุฎุชูŠุงุฑ ุงู„ู€ endocrine therapy ูŠุนุชู…ุฏ ุนู„ู‰ menopause state ุจุงู„ุงุถุงูุฉ ุงู„ู‰ ุงู„ุงุณุชุฌุงุจุฉ ู„ู„ุนู„ุงุฌุงุช ุงู„ุณุงุจู‚ุฉ ูˆ ูุชุฑุฉ ุงู„ุงุณุชุฌุงุจุฉ

ุงูŠุถุง ูŠุนุชู…ุฏ ุนู„ู‰
Mechanism of action, toxicity and pt preference

AI, Tamoxifen, Toremifen, and Fulvestrant โž” Preferred initial agent in MBC

ุจ ุงุณุชุซู†ุงุกุŒ ุงุฐุง ุงุณุชุฎุฏู…ู†ุง ูƒ adjuvant ูˆ ุจุนุฏ ุงู„ู€ Adjuvant ุฑุฌุน ุงู„ูƒุงู†ุณุฑ ุฎู„ุงู„ ุณู†ุฉ ูˆุงุญุฏุฉ ุงูˆ ุงู‚ู„ุŒ ูู…ุง ุงุฑุฌุน ุงุณุชุฎุฏู…ู‡ู† ู†ูุณู‡ู†

๐Ÿ”ต Fulvestrant im โž” approved for 2nd line therapy for Postmenopausal women with Hormone receptor positive tumor

ู…ู…ูƒู† ู„ูˆุญุฏู‡ ุงูˆ ู…ุน targeted therapy

๐Ÿ”ต LHRH agonists (goserelin, Triptorelin, and Leuprolide) โž” reversible alternative to oophorectomy in premenopausal women



โญ• Chemotherapy

ู†ุนุชุจุฑู‡ ู‡ูˆ ุงู„ู€ initial agent ููŠ ุงู„ู†ุณุงุก ุงู„ูŠ ุชูƒูˆู† :
๐ŸซŸ Hormone receptor negative tumors
๐ŸซŸ Triple negative tumors
๐ŸซŸ After failure of endocrine/targeted therapy

ูˆุงุฎุชูŠุงุฑ ุงู„ chemotherapy ูŠุนุชู…ุฏ ุนู„ู‰ ุนุฏุฉ ุนูˆุงู…ู„ ู…ู†ู‡ุง:
-overall efficacy
-the risk of toxicity
-performance status
-presence of comorbidities in the patient
-aggressiveness of disease
-patient preferences related to chemotherapy schedules
-dosing route
-frequency

ู…ู…ูƒู† ุงู„ู€ chemotherapy ุงู†ุทูŠู‡ู… ุณูˆูŠู‡
ุงูˆ ุจุทุฑูŠู‚ุฉ ู…ุชุชุงุจุนุฉ sequential ูˆู‡ูŠ ุงู„ู…ูุถู„ุฉ

๐Ÿซ† Anthracyclines and Taxane โž” first line therapy for MBC
ุจุดุฑุท ูˆุฌูˆุฏ ุงู„ุดุฑูˆุท ุงู„ุซู„ุงุซุฉ ุงุนู„ุงู‡๐ŸซŸ
ู…ุนุฏู„ุงุช ุงู„ุงุณุชุฌุงุจุฉ 50%

ูˆุฑุงู‡ุง ู…ู…ูƒู† ุงู†ุทูŠ Single agent ู…ุซู„ุง:
๐Ÿซ† Capecitabine, Vinorelbine, and gemcitabine
ู…ุนุฏู„ุงุช ุงู„ุงุณุชุฌุงุจุฉ 20-25%



โญ• Immunotherapy

๐Ÿซ† Pembrolizumab โž” mAB against PD1
ุงู†ุทูŠู‡ ุจ Combination ู…ุน:
Albumin bound Paclitaxel or
paclitaxel or
Carboplatin + Gemcitabine

๐Ÿซ† Atezolizumab โž” mAB against PDL1
ุงู†ุทูŠู‡ ุจ Combination ู…ุน
Albumin bound Paclitaxel




โญ• Radiation therapy

ู†ุณุชุฎุฏู… ุงู„ุนู„ุงุฌ ุจุงู„ุฃุดุนุงุน ู„ุนู„ุงุฌ ุงู„ู€
Painful bone metastases

ุงูˆ ุงุฐุง ู…ู†ุชุดุฑ ู„ู…ูˆุงู‚ุน ุซุงู†ูŠุฉ ุบูŠุฑ ุงู„ุนุธุงู… ู…ุซู„ุง
brain, spinal cord, eye, and orbital lesions

ุงู„ุงู„ู… ู‚ู„ ููŠ ุญูˆุงู„ูŠ 90% ู…ู† ุงู„ู…ุฑุถู‰ ุงู„ูŠ ุนุฏู‡ู… painful bone metastases ูˆุนุงู„ุฌู†ุงู‡ู… ุจ Radiation
๏ปฟ

#Breast_Cancer
โค12